Sr.Rayala.Hypo

  • Market Cap: Micro Cap
  • Industry: Commodity Chemicals
  • ISIN: INE917H01012
  • NSEID: SRHHYPOLTD
  • BSEID: 532842
INR
492.15
-10.95 (-2.18%)
BSENSE

Dec 05

BSE+NSE Vol: 14.07 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

14.07 k (43.74%) Volume

Shareholding (Sep 2025)

FII

0.06%

Held by 3 FIIs

DII

0.04%

Held by 0 DIIs

Promoter

61.84%

When is the next results date for Sr.Rayala.Hypo?

06-Jun-2025

No Upcoming Board Meetings

What does Sr.Rayala.Hypo do?

06-Jun-2025

Sree Rayalaseema Hi-Strength Hypo Ltd is a small-cap company specializing in the production of Calcium Hypochlorite, Stable Bleaching Powder, and Sulphuric Acid. As of March 2025, it reported net sales of 160 Cr and a net profit of 22 Cr.

Overview:<BR>Sree Rayalaseema Hi-Strength Hypo Ltd is a leading producer of Calcium Hypochlorite, Stable Bleaching Powder, Sulphuric Acid, and other chemicals in the commodity chemicals industry, categorized as a small-cap company.<BR><BR>History:<BR>Incorporated in March 2005, Sree Rayalaseema Hi-Strength Hypo Ltd is recognized as the only Indian manufacturer of Calcium Hypochlorite and one of the few globally. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 160 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 22 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,095 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.44% <BR>Debt-Equity: -0.39 <BR>Return on Equity: 9.78% <BR>Price to Book: 1.22 <BR><BR>Contact Details:<BR>Address: Gondiparla, Kurnool Andhra Pradesh : 518004 <BR>Tel: 91-40-23313842 <BR>Fax: 91-40-23313875 <BR>Website: http://www.srhhl.com

Read More

Has Sr.Rayala.Hypo declared dividend?

06-Jun-2025

Sree Rayalaseema Hi-Strength Hypo Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of September 12, 2024. The dividend yield is 0.44%, and while the company has shown strong long-term returns, it experienced a -9.3% total return over the last 6 months.

Sree Rayalaseema Hi-Strength Hypo Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 12 Sep 24<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.3%, the dividend return was 0%, resulting in a total return of -9.3%.<BR><BR>Over the past year, the price return was 26.45%, the dividend return was 0.54%, leading to a total return of 26.99%.<BR><BR>In the 2-year period, the price return was 4.28%, the dividend return was 1.11%, culminating in a total return of 5.39%.<BR><BR>For the 3-year period, the price return was 41.76%, the dividend return was 2.63%, which resulted in a total return of 44.39%.<BR><BR>In the last 4 years, the price return was 116.37%, the dividend return was 3.89%, yielding a total return of 120.26%.<BR><BR>Over the past 5 years, the price return was 516.93%, the dividend return was 12.61%, resulting in a total return of 529.54%.<BR><BR>Overall, while the company has declared a dividend, the recent total returns show mixed performance, with significant gains over longer periods but a negative return in the last 6 months. The dividend yield remains relatively low at 0.44%.

Read More

Who are the peers of the Sr.Rayala.Hypo?

03-Jun-2025

Peers of Sr.Rayala.Hypo include Tata Chemicals, Chemplast Sanmar, GHCL, and others, with varying management risks and capital structures. POCL Enterprises has the highest 1-year return at 236.24%, while Sr.Rayala.Hypo's return is 12.85%.

Peers: The peers of Sr.Rayala.Hypo are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Tuticorin Alkali, Transpek Inds., Sadhana Nitro, and POCL Enterprises.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar, and the rest have Average or Below Average management risk. Below Average growth is noted for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Sadhana Nitro, and the rest, while Average growth is seen at Tuticorin Alkali and Fischer Medical. Excellent capital structure is attributed to Sr.Rayala.Hypo, while Good capital structure is found at GHCL, Tuticorin Alkali, and Transpek Inds., and the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is POCL Enterprises at 236.24%, while the lowest is Sadhana Nitro at -53.28%. Sr.Rayala.Hypo's 1-year return of 12.85% is significantly lower than that of POCL Enterprises but higher than Sadhana Nitro. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Sr.Rayala.Hypo, Tuticorin Alkali, Sadhana Nitro, and Primo Chemicals.

Read More

Who are in the management team of Sr.Rayala.Hypo?

16-Jul-2025

As of March 2022, the management team of Sr.Rayala.Hypo includes TUMBALAM GOOTY BHARATH (Chairman & Managing Director), V Surekha (Company Secretary), and several directors, with Bharath receiving a remuneration of 7.14 crore INR. The other members do not have reported remuneration.

As of March 2022, the management team of Sr.Rayala.Hypo includes the following members:<BR><BR>1. TUMBALAM GOOTY BHARATH - Chairman & Managing Director<BR>2. V Surekha - Company Secretary & Compliance Officer<BR>3. Krishna Moorthy Chandraiah Naik - Director<BR>4. P. Ramachandra Gowd - Independent Director<BR>5. A. Kailashnath - Independent Director<BR>6. H Gurunath Reddy - Director<BR>7. R Triveni - Independent Director<BR><BR>The Chairman & Managing Director, TUMBALAM GOOTY BHARATH, receives a remuneration of 7.14 crore INR, while the other members listed do not have any reported remuneration.

Read More

Who are the top shareholders of the Sr.Rayala.Hypo?

17-Jul-2025

The top shareholders of Sr.Rayala.Hypo include Gowri Gopal Hospitals Private Limited with 21.8%, and individual investors who own 25.85%. There are minimal holdings from mutual funds and foreign institutional investors, with no pledged promoter holdings or significant public shareholders.

The top shareholders of Sr.Rayala.Hypo are primarily the promoters, with Gowri Gopal Hospitals Private Limited holding the largest stake at 21.8%. Additionally, individual investors collectively own 25.85% of the company. There are also some holdings by mutual funds and foreign institutional investors, but these represent a very small percentage of the overall ownership. Notably, there are no pledged promoter holdings or significant public shareholders.

Read More

How big is Sr.Rayala.Hypo?

24-Jul-2025

As of 24th July, Sree Rayalaseema Hi-Strength Hypo Ltd has a market capitalization of 1,151.00 Cr, with recent Net Sales of 637.82 Cr and a Net Profit of 87.47 Cr.

As of 24th July, Sree Rayalaseema Hi-Strength Hypo Ltd has a market capitalization of 1,151.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 637.82 Cr and a Net Profit of 87.47 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 800.61 Cr and Total Assets valued at 914.00 Cr.

Read More

Is Sr.Rayala.Hypo technically bullish or bearish?

03-Oct-2025

As of October 1, 2025, the technical trend has shifted to a moderately strong bearish stance, supported by bearish MACD, moving averages, and Bollinger Bands, along with underperformance against the Sensex.

As of 1 October 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and bearish Bollinger Bands on the weekly timeframe. The KST and OBV also indicate a mildly bearish trend on the weekly basis. The stock has underperformed significantly compared to the Sensex across multiple time frames, further reinforcing the bearish outlook.

Read More

Is Sr.Rayala.Hypo overvalued or undervalued?

15-Oct-2025

As of October 14, 2025, Sr.Rayala.Hypo is considered an attractive investment due to its undervaluation compared to peers in the commodity chemicals industry, with a PE ratio of 9.98, significantly lower than competitors like Solar Industries and Gujarat Fluoroch, despite a recent stock decline of 34.32% compared to the Sensex.

As of 14 October 2025, the valuation grade for Sr.Rayala.Hypo has moved from fair to attractive, indicating a more favorable assessment of the company's stock. The company is currently considered undervalued, especially when compared to its peers in the commodity chemicals industry. Key ratios include a PE ratio of 9.98, an EV to EBITDA of 6.47, and a PEG ratio of 0.51, which suggest that the stock is trading at a significant discount relative to its earnings growth potential.<BR><BR>In comparison to peers, Sr.Rayala.Hypo's PE ratio is substantially lower than Solar Industries, which has a PE of 99.77, and Gujarat Fluoroch at 64.04, both categorized as very expensive. Additionally, Godrej Industries, another attractive peer, has a PE of 35.44, further highlighting Sr.Rayala.Hypo's relative undervaluation. Despite recent stock performance lagging behind the Sensex, particularly over the past year with a decline of 34.32% compared to a slight increase in the Sensex, the current valuation metrics suggest that Sr.Rayala.Hypo presents a compelling investment opportunity.

Read More

How has been the historical performance of Sr.Rayala.Hypo?

17-Nov-2025

Sr.Rayala.Hypo has experienced declining net sales and profits from Mar'23 to Mar'25, with net sales dropping from 1,650.12 Cr to 637.82 Cr and profit after tax decreasing from 154.25 Cr to 87.47 Cr, despite some stabilization in cash flow and asset growth. Total liabilities and assets both increased during this period, indicating a challenging financial environment.

Answer:<BR>The historical performance of Sr.Rayala.Hypo shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sr.Rayala.Hypo's net sales have seen a decline from 1,650.12 Cr in Mar'23 to 637.82 Cr in Mar'25, indicating a downward trend in revenue. The total operating income followed a similar pattern, decreasing from 1,650.12 Cr in Mar'23 to 637.82 Cr in Mar'25. The company's total expenditure also decreased from 1,472.43 Cr in Mar'23 to 545.78 Cr in Mar'25, reflecting a reduction in operational costs. Operating profit (PBDIT) has shown a decline from 211.80 Cr in Mar'23 to 131.51 Cr in Mar'25, while profit before tax increased from 190.42 Cr in Mar'23 to 119.15 Cr in Mar'25. The profit after tax also decreased from 154.25 Cr in Mar'23 to 87.47 Cr in Mar'25. On the balance sheet, total liabilities rose from 945.02 Cr in Mar'23 to 1,069.60 Cr in Mar'25, while total assets increased from 945.02 Cr to 1,069.60 Cr in the same period. Cash flow from operating activities decreased from 141.00 Cr in Mar'23 to 65.00 Cr in Mar'25, but net cash inflow improved from 12.00 Cr to 39.00 Cr. Overall, the financial performance of Sr.Rayala.Hypo reflects a challenging environment with declining revenues and profits, yet some stabilization in cash flow and asset growth.

Read More

Are Sr.Rayala.Hypo latest results good or bad?

18-Nov-2025

Sree Rayalaseema Hi-Strength Hypo's latest results show a net profit increase to ₹23.29 crore and record revenue of ₹182.39 crore, but declining operating and profit margins raise concerns about profitability and operational efficiency. Overall, the results reflect a mixed performance with both positive growth and significant challenges.

The latest results for Sree Rayalaseema Hi-Strength Hypo present a mixed picture. On one hand, the company achieved a net profit of ₹23.29 crore for Q2 FY26, which is a 3.93% increase compared to the previous quarter. Additionally, revenue grew by 1.18% quarter-on-quarter and 7.14% year-on-year, reaching ₹182.39 crore, marking the highest quarterly revenue on record.<BR><BR>However, there are significant concerns regarding profitability. The operating margin has decreased to 14.78%, down 222 basis points year-on-year, indicating that rising input costs and competitive pressures are affecting the company's ability to maintain margins. The profit after tax (PAT) margin also fell by 209 basis points compared to the same quarter last year, despite a slight improvement from the previous quarter.<BR><BR>Overall, while there are positive signs in terms of revenue growth, the deterioration in margins and profitability metrics raises concerns about the company's operational efficiency and sustainability in the current market environment. Therefore, the results can be seen as a mix of good and bad, with underlying challenges that need to be addressed.

Read More

Should I buy, sell or hold Sr.Rayala.Hypo?

19-Nov-2025

Why is Sr.Rayala.Hypo falling/rising?

05-Dec-2025

As of 05-Dec, the stock price of Sree Rayalaseema Hi-Strength Hypo Ltd is Rs 489.00, reflecting a 2.55% decline and significant underperformance compared to the Sensex, with a year-to-date drop of 37.03%. The stock has consistently fallen over various time frames, indicating a bearish trend despite increased investor participation.

As of 05-Dec, the stock price of Sree Rayalaseema Hi-Strength Hypo Ltd is falling, currently at Rs 489.00, which reflects a decrease of Rs 12.8 or 2.55%. This decline is part of a broader trend, as the stock has been underperforming significantly compared to the benchmark Sensex and has experienced consecutive losses for the past six days, totaling a drop of 8.14% during this period.<BR><BR>Over the past week, the stock has decreased by 7.24%, while the Sensex has remained relatively stable with a slight increase of 0.01%. In the last month, the stock has fallen by 11.28%, contrasting with a 2.70% rise in the Sensex. Year-to-date, the stock is down 37.03%, while the Sensex has gained 9.69%. This trend indicates a substantial underperformance over various time frames, including a 30.23% decline over the past year, compared to a 4.83% increase in the Sensex.<BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 105.87% against the 5-day average, the overall market sentiment remains negative, contributing to the stock's downward movement.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of -2.50% over the last 5 years

 
2

Negative results in Sep 25

3

Despite the size of the company, domestic mutual funds hold only 0.02% of the company

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Commodity Chemicals

stock-summary
Market cap

INR 860 Cr (Micro Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

40

stock-summary
Dividend Yield

0.57%

stock-summary
Debt Equity

-0.40

stock-summary
Return on Equity

9.46%

stock-summary
Price to Book

0.86

Revenue and Profits:
Net Sales:
182 Cr
(Quarterly Results - Sep 2025)
Net Profit:
23 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.57%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.9%
0.48%
-20.42%
6 Months
-24.86%
0.46%
-24.4%
1 Year
-29.96%
0.40%
-29.56%
2 Years
-6.84%
1.02%
-5.82%
3 Years
-10.22%
2.06%
-8.16%
4 Years
52.25%
4.12%
56.37%
5 Years
107.26%
6.54%
113.8%

Latest dividend: 3 per share ex-dividend date: Sep-19-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Why is Sr.Rayala.Hypo falling/rising?

Recent Price Movement and Market Performance

The stock has been on a losing streak for the past five consecutive days, shedding 5.7% over this period. Despite opening the day with a positive gap of 2.21% and touching an intraday high of ₹523.8, the price ultimately fell to an intraday low of ₹498, closing near the lower end of the day’s range. This pattern suggests selling pressure intensified as the trading session progressed, with a weighted average price indicating that more volume was traded closer to the day’s low.

Moreover, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook. This technical weakness is compounded by the stock’s underperformance relative to i...

Read More
Announcements stock-summary

Sree Rayalaseema Hi-Strength Hypo Limited - Press Release

15-Nov-2019 | Source : NSE

Sree Rayalaseema Hi-Strength Hypo Limited has informed the Exchange regarding a press release dated November 14, 2019, titled "press release of Q2FY2020 and H1FY2020 ".

Sree Rayalaseema Hi-Strength Hypo Limited - Updates

17-Oct-2019 | Source : NSE

Sree Rayalaseema Hi-Strength Hypo Limited has informed the Exchange regarding 'Submission of certificate under 74(5) of SEBI( Depositories and Participants ) Regulations, 2018'.

Updates

09-Sep-2019 | Source : NSE

Sree Rayalaseema Hi-Strength Hypo Limited has informed the Exchange regarding ':Submission of newspaper cuttings with regard to date of 14th Annual General Meeting date of Book closures paper ads.'.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Sree Rayalaseema Hi-Strength Hypo Ltd has declared 30% dividend, ex-date: 19 Sep 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.50%
EBIT Growth (5y)
4.43%
EBIT to Interest (avg)
43.46
Debt to EBITDA (avg)
0.21
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.50
Tax Ratio
25.99%
Dividend Payout Ratio
5.72%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
22.61%
ROE (avg)
13.39%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
40
Price to Book Value
0.84
EV to EBIT
5.17
EV to EBITDA
4.76
EV to Capital Employed
0.73
EV to Sales
0.66
PEG Ratio
1.10
Dividend Yield
0.58%
ROCE (Latest)
14.05%
ROE (Latest)
9.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 3 Schemes (0.01%)

FIIs

Held by 3 FIIs (0.06%)

Promoter with highest holding

Gowri Gopal Hospitals Private Limited (21.8%)

Highest Public shareholder

None

Individual Investors Holdings

26.12%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 1.18% vs 12.33% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 3.93% vs 1.91% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "182.39",
          "val2": "180.26",
          "chgp": "1.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "26.95",
          "val2": "27.92",
          "chgp": "-3.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.42",
          "val2": "0.42",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-4.76",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "23.29",
          "val2": "22.41",
          "chgp": "3.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.78%",
          "val2": "15.49%",
          "chgp": "-0.71%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 7.02% vs -30.32% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 5.51% vs 2.64% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "362.65",
          "val2": "338.87",
          "chgp": "7.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "54.88",
          "val2": "54.61",
          "chgp": "0.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.84",
          "val2": "0.92",
          "chgp": "-8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.76",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "46.34",
          "val2": "43.92",
          "chgp": "5.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.13%",
          "val2": "16.12%",
          "chgp": "-0.99%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -31.89% vs -42.31% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 10.20% vs -28.54% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "477.34",
          "val2": "700.84",
          "chgp": "-31.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "74.41",
          "val2": "83.56",
          "chgp": "-10.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.29",
          "val2": "1.90",
          "chgp": "-32.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-5.87",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "65.48",
          "val2": "59.42",
          "chgp": "10.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.59%",
          "val2": "11.92%",
          "chgp": "3.67%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -26.35% vs -47.52% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 10.76% vs -48.80% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "637.82",
          "val2": "866.01",
          "chgp": "-26.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "92.04",
          "val2": "110.57",
          "chgp": "-16.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.98",
          "val2": "3.98",
          "chgp": "-50.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.06",
          "val2": "-10.86",
          "chgp": "71.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "87.47",
          "val2": "78.97",
          "chgp": "10.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.43%",
          "val2": "12.77%",
          "chgp": "1.66%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary
Sep'25
Jun'25
Change(%)
Net Sales
182.39
180.26
1.18%
Operating Profit (PBDIT) excl Other Income
26.95
27.92
-3.47%
Interest
0.42
0.42
Exceptional Items
0.00
-4.76
100.00%
Consolidate Net Profit
23.29
22.41
3.93%
Operating Profit Margin (Excl OI)
14.78%
15.49%
-0.71%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 1.18% vs 12.33% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 3.93% vs 1.91% in Jun 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
362.65
338.87
7.02%
Operating Profit (PBDIT) excl Other Income
54.88
54.61
0.49%
Interest
0.84
0.92
-8.70%
Exceptional Items
-4.76
0.00
Consolidate Net Profit
46.34
43.92
5.51%
Operating Profit Margin (Excl OI)
15.13%
16.12%
-0.99%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 7.02% vs -30.32% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 5.51% vs 2.64% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
477.34
700.84
-31.89%
Operating Profit (PBDIT) excl Other Income
74.41
83.56
-10.95%
Interest
1.29
1.90
-32.11%
Exceptional Items
0.00
-5.87
100.00%
Consolidate Net Profit
65.48
59.42
10.20%
Operating Profit Margin (Excl OI)
15.59%
11.92%
3.67%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -31.89% vs -42.31% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 10.20% vs -28.54% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
637.82
866.01
-26.35%
Operating Profit (PBDIT) excl Other Income
92.04
110.57
-16.76%
Interest
1.98
3.98
-50.25%
Exceptional Items
-3.06
-10.86
71.82%
Consolidate Net Profit
87.47
78.97
10.76%
Operating Profit Margin (Excl OI)
14.43%
12.77%
1.66%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -26.35% vs -47.52% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 10.76% vs -48.80% in Mar 2024

stock-summaryCompany CV
About Sree Rayalaseema Hi-Strength Hypo Ltd stock-summary
stock-summary
Sree Rayalaseema Hi-Strength Hypo Ltd
Micro Cap
Commodity Chemicals
Sree Rayalaseema Hi-Strength Hypo Ltd was incorporated in March, 2005. The Company is the leading producer of Calcium Hypo Chloride, Stable Bleaching Powder, Sulphuric Acid and other chemicals. Sree Rayalaseema Hi-Strength Hypo, the torch bearer of the conglomerate, is the only Indian manufacturer of Calcium Hypochlorite, and one of the very few in the world.
Company Coordinates stock-summary
Company Details
Gondiparla , Kurnool Andhra Pradesh : 518004
stock-summary
Tel: 91-40-23313842
stock-summary
Registrar Details
Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad